高危超分割放疗治疗前列腺癌的早期耐受性与肿瘤控制结果
本研究纳入551例低危和中危前列腺癌患者,接受37.5-40Gy分5次立体定向体部放疗(SBRT)。中位随访17个月,5年PSA失败累积发生率为2.1%,2年治疗活检阳性率为12%。晚期2级和3级泌尿生殖毒性分别为21.1%和2.5%,水凝胶直肠间隔物使用与晚期胃肠道及泌尿生殖毒性降低显著相关。
要点
- 37.5-40Gy分5次SBRT在低中危前列腺癌中短期肿瘤控制良好,5年PSA失败率2.1%。
- 晚期2级泌尿生殖毒性达21.1%,3级为2.5%,需关注晚期毒性。
- 水凝胶直肠间隔物使用与晚期胃肠道和泌尿生殖毒性降低显著相关。
核心结论
- 高危SBRT对低中危前列腺癌取得良好短期结局,但存在严重晚期毒性,肿瘤控制良好。
研究设计与样本
- 回顾性分析551例低危或中危前列腺癌患者,接受37.5-40Gy分5次SBRT,中位随访17个月。
主要发现
- 急性2级胃肠道毒性发生率为1.8%,晚期2级和3级胃肠道毒性分别为3.4%和0.4%。
- 急性2级泌尿生殖毒性发生率为10%,3级为0.7%;晚期2级和3级泌尿生殖毒性分别为21.1%和2.5%。
- 水凝胶直肠间隔物使用与晚期胃肠道毒性降低及晚期泌尿生殖毒性几率降低显著相关。
- 5年PSA失败累积发生率为2.1%,2年治疗活检阳性率为12%。
关键数值与推荐
- 放疗剂量37.5-40Gy分5次,靶区为前列腺和精囊。
- 急性毒性定义为放疗后<3个月,晚期毒性定义为>3个月。
- 随访至少2年的患者中53%(103/193)接受了活检。
临床怎么用
- 高危SBRT可作为低中危前列腺癌的治疗选择,但需密切监测晚期泌尿生殖毒性。
- 考虑使用水凝胶直肠间隔物以降低晚期胃肠道和泌尿生殖毒性风险。
局限性
- 回顾性研究设计。
- 随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies using stereotactic body radiotherapy (SBRT) dose escalation in in low- and intermediate-risk prostate cancer patients have indicated favorable outcomes. OBJECTIVE: To evaluate tolerance and tumor control outcomes in low- and intermediate-risk prostate cancer patients treated with high-dose SBRT following our phase 1 trial. DESIGN, SETTING, AND PARTICIPANTS: A total of 551 patients with low- or intermediate-risk prostate cancer were treated with SBRT. INTERVENTION: Treatment with 37.5-40Gy SBRT in five fractions directed to the prostate and seminal vesicles. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcome measurements included acute toxicities (<3 mo after radiotherapy [RT]) and late toxicities (>3 mo after RT) and tumor control evaluation (prostate-specific antigen [PSA] levels at 3-6-mo intervals and post-treatment prostate biopsy at 2yr). RESULTS AND LIMITATIONS: Acute grade 2 gastrointestinal (GI) toxicities occurred in 1.8% of patients, and late grade 2 and 3 GI toxicities were observed in 3.4% and 0.4% of patients, respectively. Acute grade 2 genitourinary (GU) toxicities occurred in 10% of patients, and grade 3 acute GU toxicities were observed in 0.7% of patients. Late grade 2 and 3 GU toxicities were observed in 21.1% and 2.5% of patients, respectively. The use of a hydrogel rectal spacer was significantly associated with reduced late GI toxicity and lower odds of developing late GU toxicity. The median follow-up was 17 mo, and 53% of those with at least 2yr of follow-up (103/193) had a biopsy performed. The 5-yr cumulative incidence of PSA failure was 2.1%, and the incidence of a positive 2-yr treatment biopsy was 12%. Limitations to this report include its retrospective nature and short follow-up time. CONCLUSIONS: Favorable short-term outcomes were achieved with high-dose SBRT for low- and intermediate-risk disease. Severe late toxicities were observed and favorable tumor control was found. PATIENT SUMMARY: We utilized stereotactic body radiotherapy, a form of external beam radiotherapy that delivers highly targeted high-dose treatment to the prostate, to treat over 500 localized prostate cancer patients in five sessions over 1.5 wk. Treatments were well tolerated without significant urinary or rectal side effects. Nearly 90% of those who underwent biopsies after treatment did not demonstrate residual active disease.
引用
- Zelefsky MJ, Pinitpatcharalert A, Kollmeier M, et al. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31668713. doi:10.1016/j.euo.2019.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。